Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 See also 2 References

N-Methyl-PPPA

Add links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version Appearance From Wikipedia, the free encyclopedia

N-Methyl-PPPA
Clinical data

Other names	Detrifluoromethylfluoxetine
ATC code	None
Identifiers
IUPAC name N-Methyl-3-phenoxy-3-phenyl-1-propanamine
ChemSpider	16340904
Chemical and physical data
Formula	C₁₆H₁₉NO
Molar mass	241.334 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CNCCC(Oc1ccccc1)c2ccccc2
InChI InChI=1S/C16H19NO/c1-17-13-12-16(14-8-4-2-5-9-14)18-15-10-6-3-7-11-15/h2-11,16-17H,12-13H2,1H3 Key:DMOUAPYFRKLFHO-UHFFFAOYSA-N

N-Methyl-PPPA, or N-methyl-3-phenoxy-3-phenylpropan-1-amine, is a serotonin-norepinephrine reuptake inhibitor (SNRI) which was developed by Eli Lilly from diphenhydramine in the early 1970s while in search of new antidepressants, but was never marketed.^[1]^[2]^[3] It is closely related structurally to fluoxetine, atomoxetine, and nisoxetine.^[1]^[2]^[3]

References[edit]

^ ^a ^b López-Muñoz F, Álamo C (9 September 2011). "Contribution of Pharmacology to Development of Monoaminergic Hypothesis". In Lopez-Munoz F, Alamo C (eds.). Neurobiology of Depression. CRC Press. pp. 132–. ISBN 978-1-4398-3850-1.

^ ^a ^b Sneader W (31 October 2005). "Drugs Originating from the Screening of Organic Chemicals". Drug Discovery: A History. John Wiley & Sons. pp. 416–417. doi:10.1002/0470015535.ch28. ISBN 978-0-470-01552-0.

^ ^a ^b Wong DT, Bymaster FP, Engleman EA (1995). "Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication". Life Sciences. 57 (5): 411–441. doi:10.1016/0024-3205(95)00209-o. PMID 7623609.

Antidepressants (N06A)

Specific reuptake inhibitors and/or receptor modulators

SSRIsTooltip Selective serotonin reuptake inhibitors	Citalopram Escitalopram Fluoxetine^# Fluvoxamine Indalpine^‡ Paroxetine Sertraline Zimelidine^‡
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors	Desvenlafaxine Duloxetine Levomilnacipran Milnacipran Tofenacin Venlafaxine
NRIsTooltip Norepinephrine reuptake inhibitors	Atomoxetine Reboxetine Viloxazine
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors	Amineptine^‡ Bupropion Nomifensine^‡
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants	Mianserin Mirtazapine Setiptiline
SARIsTooltip Serotonin antagonist and reuptake inhibitors	Etoperidone Nefazodone Trazodone
SMSTooltip Serotonin modulator and stimulators	Vilazodone Vortioxetine
Others	Agomelatine Amisulpride Dextromethorphan/bupropion Esketamine Etryptamine^‡ Gepirone Indeloxazine Flupentixol Ketamine^§ Medifoxamine^‡ Metryptamine^‡ Oxaflozane^‡ Pivagabine^‡ Tandospirone Teniloxazine Tianeptine